Just saw that Leerink Partners gave SpyGlass Pharma an Outperform rating last month. Not sure if anyone's paying attention to SGP right now, but apparently they think there's potential here. The fund positioning is pretty thin though - barely any institutions holding it according to the data. Huntington National Bank has a small position but nothing major. SpyGlass hasn't really moved much in terms of institutional interest over the last quarter. Interesting that an analyst firm would initiate coverage on a stock with such low fund sentiment. Could be early on something or just nobody's interested yet. Might be worth keeping an eye on if you're into pharma plays, but definitely not a crowded trade. Anyone else following SpyGlass or is this totally under the radar?